VERTEX PHARMACEUTICALS INC / MA (VRTX) Share buybacks
- Total buybacks · last 12 months (USD): Value $2.01B; Formula and calculation Trailing-year cash paid for share repurchases. Period ending 2026-06-30..
- Buyback yield · 12 months: Value (m); Formula and calculation Cash paid for share repurchases / current market cap. Period ending 2026-06-30..
Share buybacks
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total buybacks · last 12 months (USD) | $2.01B | Trailing-year cash paid for share repurchases. Period ending 2026-06-30. |
| Buyback yield · 12 months | (m) | Cash paid for share repurchases / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Buybacks · 12 months | 2.01B USD | Payments for Repurchase of Common Stock |
| Market cap | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total buybacks | Market cap (USD) | Buyback yield |
|---|---|---|---|
| 2026-06-30 | $2.01B | (m) | (m) |
| 2026-03-31 | $1.93B | (m) | (m) |
| 2025-12-31 | $2.02B | (m) | (m) |
| 2025-09-30 | $2.31B | (m) | (m) |
| 2025-06-30 | $1.54B | (m) | (m) |
| 2025-03-31 | $1.47B | (m) | (m) |
| 2024-12-31 | $1.18B | (m) | (m) |
| 2024-09-30 | $908.70M | (m) | (m) |
| 2024-06-30 | $718.00M | (m) | (m) |
| 2024-03-31 | $426.00M | (m) | (m) |
| 2023-12-31 | $427.60M | (m) | (m) |
| 2023-09-30 | $278.10M | (m) | (m) |
| 2023-06-30 | $161.10M | (m) | (m) |
| 2023-03-31 | $132.80M | (m) | (m) |
| 2022-12-31 | $0.00 | (m) | (m) |
| 2022-09-30 | $368.20M | (m) | (m) |
| 2022-06-30 | $1.00B | (m) | (m) |
| 2022-03-31 | $1.00B | (m) | (m) |
| 2021-12-31 | $1.43B | (m) | (m) |
| 2021-09-30 | $1.19B | (m) | (m) |
| 2021-06-30 | $664.06M | (m) | (m) |
| 2021-03-31 | $664.06M | (m) | (m) |
| 2020-12-31 | $539.14M | (m) | (m) |
| 2020-09-30 | $450.03M | (m) | (m) |
| 2020-06-30 | $342.02M | (m) | (m) |
| 2020-03-31 | $398.03M | (m) | (m) |
| 2019-12-31 | $192.01M | (m) | (m) |
| 2019-09-30 | $298.96M | (m) | (m) |
| 2019-06-30 | $390.86M | (m) | (m) |
| 2019-03-31 | $439.88M | (m) | (m) |
| 2018-12-31 | $350.04M | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) |
| 2017-12-31 | $0.00 | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) |
| 2016-12-31 | $0.00 | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |